These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37800604)

  • 1. Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus.
    Gensous N; Lazaro E; Blanco P; Richez C
    Expert Rev Clin Immunol; 2024; 20(1):21-30. PubMed ID: 37800604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of anifrolumab for use in adults with systemic lupus erythematosus.
    Ahmed AA; Osman N; Furie R
    Expert Rev Clin Immunol; 2022 Nov; 18(11):1095-1106. PubMed ID: 36083692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials.
    Tanaka Y; Tummala R
    Mod Rheumatol; 2021 Jan; 31(1):1-12. PubMed ID: 32814461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date.
    Felten R; Scher F; Sagez F; Chasset F; Arnaud L
    Drug Des Devel Ther; 2019; 13():1535-1543. PubMed ID: 31190735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab.
    Tang W; Tummala R; Almquist J; Hwang M; White WI; Boulton DW; MacDonald A
    Clin Pharmacokinet; 2023 May; 62(5):655-671. PubMed ID: 37148484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.
    Baker T; Sharifian H; Newcombe PJ; Gavin PG; Lazarus MN; Ramaswamy M; White WI; Ferrari N; Muthas D; Tummala R; Morand EF; Furie RA; Vital EM; Chamberlain C; Platt A; Al-Mossawi H; Brohawn PZ; Csomor E
    Ann Rheum Dis; 2024 Jul; 83(8):1018-1027. PubMed ID: 38569851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review.
    Liu Z; Cheng R; Liu Y
    Front Immunol; 2022; 13():996662. PubMed ID: 36211347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials.
    Tummala R; Abreu G; Pineda L; Michaels MA; Kalyani RN; Furie RA; Morand EF
    Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33597205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological actions of anifrolumab (Saphnelo
    Ueha T; Kusuda M; Shibata S; Hirata M; Ozaki N
    Nihon Yakurigaku Zasshi; 2022; 157(4):271-279. PubMed ID: 35781459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-IFNαR Mabs for the treatment of systemic lupus erythematosus.
    Goulden B; Isenberg D
    Expert Opin Biol Ther; 2021 Apr; 21(4):519-528. PubMed ID: 33085537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations.
    Anderson E; Furie R
    Immunotherapy; 2020 Apr; 12(5):275-286. PubMed ID: 32237942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anifrolumab in systemic lupus erythematosus.
    Loncharich MF; Robertson I
    Drugs Today (Barc); 2023 Feb; 59(2):53-61. PubMed ID: 36811405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
    Morand EF; Furie R; Tanaka Y; Bruce IN; Askanase AD; Richez C; Bae SC; Brohawn PZ; Pineda L; Berglind A; Tummala R;
    N Engl J Med; 2020 Jan; 382(3):211-221. PubMed ID: 31851795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
    Vital EM; Merrill JT; Morand EF; Furie RA; Bruce IN; Tanaka Y; Manzi S; Kalunian KC; Kalyani RN; Streicher K; Abreu G; Tummala R
    Ann Rheum Dis; 2022 Jul; 81(7):951-961. PubMed ID: 35338035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus.
    Casey KA; Smith MA; Sinibaldi D; Seto NL; Playford MP; Wang X; Carlucci PM; Wang L; Illei G; Yu B; Wang S; Remaley AT; Mehta NN; Kaplan MJ; White WI
    Arthritis Rheumatol; 2021 Mar; 73(3):459-471. PubMed ID: 32909675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
    Furie RA; Morand EF; Bruce IN; Manzi S; Kalunian KC; Vital EM; Lawrence Ford T; Gupta R; Hiepe F; Santiago M; Brohawn PZ; Berglind A; Tummala R;
    Lancet Rheumatol; 2019 Dec; 1(4):e208-e219. PubMed ID: 38229377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R; Khamashta M; Merrill JT; Werth VP; Kalunian K; Brohawn P; Illei GG; Drappa J; Wang L; Yoo S;
    Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis.
    Tanaka Y; Atsumi T; Okada M; Miyamura T; Ishii T; Nishiyama S; Matsumura R; Hayashi N; Abreu G; Tummala R; Morand EF; Takeuchi T
    Mod Rheumatol; 2023 Jan; 33(1):134-144. PubMed ID: 35134970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.
    Bruce IN; Furie RA; Morand EF; Manzi S; Tanaka Y; Kalunian KC; Merrill JT; Puzio P; Maho E; Kleoudis C; Albulescu M; Hultquist M; Tummala R
    Ann Rheum Dis; 2022 Jul; 81(7):962-969. PubMed ID: 35580976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.